OasisLMS

1. Describe the unique clinical, pharmacologic, and psychosocial considerations in the care of transgender and gender-diverse people with epilepsy.
2. Understand the bidirectional interplay between gender-affirming hormone therapy and antiseizure medications, including effects on seizure control and hormone levels.
3. Identify potential drug-hormone interactions and barriers to care in sample patient scenarios involving gender-affirming care.
4. Analyze how stigma, discrimination, and systemic barriers affect access, adherence, and outcomes for LGBTQ+ patients with epilepsy.
5. Evaluate current clinic practices, such as intake forms, language, and records, for inclusivity and gaps in affirming care.
6. Develop a practical action plan to build inclusive, patient-centered epilepsy care environments that support equitable, high-quality care. 

Faculty:

Sasha Alick-Lindstrom, MD, MPH, FAAN, FACNS, FAES

Pronouns: She/Her/Hers/Ella

Associate Professor, Departments of Radiology and Neurology

Magnetoencephalography Clinical Epilepsy Director, MEG Center of Excellence

Division of Neuroradiology

Department of Radiology

Epilepsy, Neurophysiology, and Neurology

Department of Neurology

Peter O’Donnell Jr Brain Institute

UT Southwestern Medical Center in Dallas, TX

Moderator:

Shilpa Klocke, PharmD, BCPS
Shilpa Klocke, PharmD, BS Pharm, BCPS has been a clinical pharmacy specialist for Kaiser Permanente in Colorado for more than 20 years where she has specialized in Neurology for than 17 years. In this role, she provides multiple sclerosis (MS) disease modifying therapy - related patient counseling, helped to create an MS population management safety monitoring program that utilizes a collaborative drug therapy management protocol and trains and provides mentorship to pharmacists throughout Kaiser Permanente who will become specialists in MS. She publishes research activities in MS and epilepsy, and precepts pharmacy students and residents. She is also employed as a part-time consultant on the Editorial Advisory Panel for Wolters Kluwer Health, Clinical Effectiveness Division and is an appointed member of the Health First Colorado (Colorado’s Medicaid Program) Drug Utilization Review board. In addition to MS, her clinical practice interests include epilepsy, headache, movement disorders, as well as, designing patient safety and medication cost-effectiveness processes. Dr. Klocke earned her Doctor of Pharmacy degree at the University of Wisconsin-Madison and completed PGY1 and PGY2 pharmacy practice residencies at Parkland Health & Hospital System in Dallas, Texas.